Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Stage IIB Prostate Cancer peptide trials
3 selected ClinicalTrials.gov records carrying the official condition label Stage IIB Prostate Cancer. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
3 selected records.
3 profiles.
2015–2019 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 109 selected PubMed records and 28 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Stage IIB Prostate Cancer unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT00108732
PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- June 30, 2015
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT01731912
PeptideScanner retained ClinicalTrials.gov record NCT01731912 at 2026-11-15T21:52:09.579Z. Its registry update date was 2019-01-18, and PeptideScanner's reviewed identity mapping was degarelix.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- January 18, 2019
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT00589472
PeptideScanner retained ClinicalTrials.gov record NCT00589472 at 2026-07-30T21:22:00.251Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was leuprolide.
- PeptideScanner change date
- August 13, 2026
- Cited source date
- October 6, 2017
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Degarelix · 2019-01-18
ClinicalTrials.gov record NCT01731912
Completed at the retained observation.
Open attributed record →Leuprolide · 2017-10-06
ClinicalTrials.gov record NCT00589472
Completed at the retained observation.
Open attributed record →Goserelin · 2015-06-30
ClinicalTrials.gov record NCT00108732
Completed at the retained observation.
Open attributed record →